Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report
- Authors:
- Yi‑Chen Liang
- Gang Wu
- Jing Cheng
- Dan‑Dan Yu
- Hong‑Ge Wu
View Affiliations
Affiliations: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
- Published online on: July 8, 2015 https://doi.org/10.3892/ol.2015.3463
-
Pages:
1277-1280
-
Copyright: © Liang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, which is used to treat patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Dermatological reactions are the most common adverse events associated with gefitinib treatment; other adverse effects, including diarrhea, nausea, stomatitis and an asymptomatic elevation of liver enzymes have also been reported. The present study describes a patient with intestinal obstruction who was successfully undergoing treatment with gefitinib for primary and metastatic neoplasms. Gefitinib‑induced intestinal obstruction has not been previously reported; therefore, careful monitoring of gastrointestinal symptoms should be conducted throughout the course of gefitinib-treated malignancies.
View References
|
1
|
Shepherd FA, Dancey J, Ramlau R, et al:
Prospective randomized trial of docetaxel versus best supportive
care in patients with non-small-cell lung cancer previously treated
with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103.
2000.PubMed/NCBI
|
|
2
|
Ettinger DS: Clinical implications of EGFR
expression in the development and progression of solid tumors:
Focus on non-small cell lung cancer. Oncologist. 11:358–373. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haaland B, Tan PS, de Castro G Jr and
Lopes G: Meta-analysis of first-line therapies in advanced
non-small-cell lung cancer harboring EGFR-activating mutations. J
Thorac Oncol. 9:805–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Faivre S, Delbaldo C, Vera K, et al:
Safety, pharmacokinetic and antitumor activity of SU11248, a novel
oral multitarget tyrosine kinase inhibitor, in patients with
cancer. J Clin Oncol. 24:25–35. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hartmann JT and Kanz L: Sunitinib and
periodic hair depigmentation due to temporary c-KIT inhibition.
Arch Dermatol. 144:1525–1526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hotta K, Kiura K, Takigawa N, et al:
Comparison of the incidence and pattern of interstitial lung
disease during erlotinib and gefitinib treatment in Japanese
patients with non-small cell lung cancer: The Okayama Lung Cancer
Study Group experience. J Thorac Oncol. 5:179–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakagawa M, Nishimura T, Teramukai S, et
al: Interstitial lung disease in gefitinib-treated Japanese
patients with non-small cell lung cancer - a retrospective
analysis: JMTO LC03-02. BMC Res Notes. 2:1572009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Passaro A, Di Maio M, Del Signore E, Gori
B and de Marinis F: Management of nonhematologic toxicities
associated with different EGFR-TKIs in advanced NSCLC: A comparison
analysis. Clin Lung Cancer. 15:307–312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Madke B, Gole P, Kumar P and Khopkar U:
Dermatological side effects of epidermal growth factor receptor
inhibitors: ‘PRIDE’ complex. Indian J Dermatol. 59:271–274. 2014.
View Article : Google Scholar : PubMed/NCBI
|
